Merck & Co., Inc. (MRK) Files Form 4 Insider Selling : Kenneth C Frazier Sells 131,040 Shares

Merck & Co., Inc. (MRK): Kenneth C Frazier , Chairman, President & CEO of Merck & Co., Inc. sold 131,040 shares on Apr 14, 2016. The Insider selling transaction was reported by the company on Apr 14, 2016 to the Securities and Exchange Commission. The shares were sold at $56.11 per share for a total value of $7,352,942.50 according the SEC Form 4 Filing.

Company has been under the radar of several Street Analysts.Merck & Co. is Initiated by Societe Generale to Buy and the brokerage firm has set the Price Target at $80. The Rating was issued on Apr 6, 2016.Merck & Co. is Downgraded by BofA/Merrill to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jan 27, 2016.

Currently the company Insiders own 0.22% of Merck & Co. shares according to the proxy statements.Institutional Investors own 72.9% of Merck & Co. shares.

Shares of Merck & Co. (MRK) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.31 points or -0.56% at $55.05 with 70,65,601 shares getting traded. Post opening the session at $55.37, the shares hit an intraday low of $54.98 and an intraday high of $55.74 and the price vacillated in this range throughout the day. The company has a market cap of $152,778 M and the number of outstanding shares has been calculated to be 2,77,52,58,600 shares. The 52-week high of Merck & Co. is $61.7 and the 52-week low is $45.69.

Merck & Co. Money Flow Index Chart

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.